New U.S. study finds mRNA-1273.815, a monovalent vaccine targeting the Omicron XBB.1.5 variant, generates higher neutralizing antibody titers compared to its bivalent counterpart. The study supports updating to an XBB.1.5-based monovalent vaccine for the 2023-24 campaign to combat emerging variants.
Could Metformin Fill the Bill for Geographic Atrophy Prevention?
STOCKHOLM — The risk of developing geographic atrophy (GA) declined significantly in patients who had a history of treatment with metformin, a case-control study involving
July 23, 2024